We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

The Conversion of ENcapsulated GlucorAphanin, Gut Microbiota Phylogeny and gEnotype Study (ENGAGE) (ENGAGE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01927666
Recruitment Status : Completed
First Posted : August 22, 2013
Last Update Posted : September 5, 2016
Biotechnology and Biological Sciences Research Council
The Danish Council for Strategic Research
Information provided by (Responsible Party):
Quadram Institute Bioscience

Brief Summary:

The variation in extent of isothiocyanate (ITC) excretion in urine from a capsule delivered dose of glucoraphanin will correlate with differences in (a) the gut microbiota, and (b) the genotype of key polymorphic genes (GSTM1, GSTT1, and other as yet undetermined candidate genes).

Our study is a human dietary intervention in which participants will consume one capsule containing 100mg purified glucoraphanin from broccoli. The levels of glucoraphanin delivered by the capsule are similar to one to two portions of broccoli. As this is purified glucoraphanin there is no myrosinase enzyme present. All conversion of the glucoraphanin, contained within the capsule, to ITC will therefore occur by enzymes found in the gut microbiota.

The ability of the glucoraphanin in the capsule to be metabolised to ITCs by the gut microflora is unknown and will be assessed by measuring ITCs excreted in the urine. The ITCs will be quantified in urine using validated analytical methods.

It has been shown in human dietary intervention studies that the extent of conversion of glucosinolates varies greatly. In order to assess possible causative factors for variation in rate of glucoraphanin metabolism each participant will provide a faecal sample from which their faecal gut microbiota phylogeny will be analysed.

For a small number of participants a second faecal sample will be requested (a maximum of 3 participants). It is our aim to select one low, one medium and one high ITC excreter. Ideally the low and high excreters would be within the lowest and highest 5% excretion of ITC and the third participant would be as close to the mean ITC excretion as possible. The aim would be to culture the faecal microbiota over time with repeat dosing of glucoraphanin in order to select for microbiota that are able to metabolise glucoraphanin. It is known that the main hydrolysis product of glucoraphanin, sulforaphane, has a variety of benefits to human health, however there is no known clinical relevance to being a high, medium or low excreter of ITC.

For each participant a blood sample will also be requested in order that we can assess whether genotype affects the rate of ITC excretion in urine. The GSTM1 genotype and other, as yet, unidentified candidate genes of each participant will be determined. Whether the genotype affects the rate of ITC excretion either alone or in combination with the phylogenetic profile will be assessed.

Condition or disease Intervention/treatment Phase
Healthy Dietary Supplement: 100mg glucoraphanin Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 57 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Human Intervention Trial Investigating the Conversion of Encapsulated Glucoraphanin to Isothiocyanates; and the Potential Link Between the Extent of the Conversion to an Individual's Gut Microbiota Phylogeny and Genotype.
Study Start Date : December 2012
Actual Primary Completion Date : December 2014
Actual Study Completion Date : August 2016

Arm Intervention/treatment
Experimental: dietary intervention
To measure the variation in extent of ITC excretion in urine from a capsule delivered dose of 100mg glucoraphanin
Dietary Supplement: 100mg glucoraphanin
The extent of ITC excretion in urine from a capsule delivered dose of glucoraphanin

Primary Outcome Measures :
  1. Urinary ITC concentration [ Time Frame: In 24h collections at (i) baseline and (ii) following glucoraphanin capsule administration. ]
    To measure urinary ITC by HP-LC and LC-MS using validated methods in urine collected during a dietary restriction period both before and after (24 hour urine collection) consumption of a 100mg glucoraphanin capsule.

Secondary Outcome Measures :
  1. Faecal microbiota phylogenetic analysis [ Time Frame: At baseline ]
    To measure gut microbiota populations by faecal bacteria phylogenetic analysis.

  2. Genotype [ Time Frame: At baseline ]
    To determine the genotype of participants for key polymorphic genes by PCR on DNA extracted from blood.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Men and women aged 18 or over
  • Smokers and non-smokers
  • Those that live within 40 miles, and 2 hours travelling time, of Norwich

Exclusion Criteria:

  • Women who are or have been pregnant within the last 12 months or breast feeding.
  • Those currently suffering from or have ever suffered from any gastrointestinal disease, gastrointestinal disorders and/or surgery including regular diarrhoea and constipation (excluding hiatus hernia unless symptomatic) or study intervention/procedure is contraindicated.
  • Have been diagnosed with any long-term medical condition that may affect the study outcome (e.g. diabetes, haemophilia, cardiovascular disease, glaucoma, anaemia). These will be assessed on an individual basis.
  • On medication that may affect the study outcome.
  • Those that have used antibiotics within the previous one month or on long-term antibiotic therapy.
  • Those regularly taking laxatives (once a month or more)
  • Those intermittently using pre &/or pro biotics unless willing to abstain for 1 month prior and during study period. (If used regularly (3+ times a week, and for more than one month) and will continue throughout study period then do not exclude).
  • Those taking dietary supplements or herbal remedies which may affect the study outcome -unless the participant is willing to discontinue taking them for 1 month prior to starting study. Please note that some supplements may not affect the study and this will be assessed on an individual basis
  • Regular/ recent (within 3 months) use of colonic irrigation or other bowel cleansing techniques.
  • Parallel participation in another research project which involves dietary intervention and/or sampling of blood
  • Any person related to or living with any member of the study team
  • Participation in another research project which involves blood sampling within the last four months unless total blood from both studies does not exceed 470mL
  • are unwilling to provide GPs contact details
  • are unable to provide written informed consent
  • are not suitable to take part in this study because of your screening results
  • have donated or intend to donate blood within 16 weeks of the first and last study samples
  • Those with a body mass index (BMI, kg/m2) <20
  • Those who are unable to swallow capsules
  • Those who do not have access to a freezer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01927666

Layout table for location information
United Kingdom
Institute Of Food Research
Norwich, Norfolk, United Kingdom, NR4 7UA
Sponsors and Collaborators
Quadram Institute Bioscience
Biotechnology and Biological Sciences Research Council
The Danish Council for Strategic Research
Layout table for investigator information
Principal Investigator: Richard Mithen, PhD Quadram Institute Bioscience
Layout table for additonal information
Responsible Party: Quadram Institute Bioscience
ClinicalTrials.gov Identifier: NCT01927666    
Other Study ID Numbers: 12/EE/0483
First Posted: August 22, 2013    Key Record Dates
Last Update Posted: September 5, 2016
Last Verified: November 2015
Keywords provided by Quadram Institute Bioscience:
gut microbiota